PLX · Company research
Protalix BioTherapeutics, Inc. Common Stock (PLX): Valuation Analysis
Available valuation snapshots and ratios; unavailable metrics remain blank.
RESEARCH CONTEXT
Understand the numbers
Available valuation snapshots and ratios; unavailable metrics remain blank. Use period, currency, units and source fields when interpreting values.
1records availableHealthcare
Valuation Analysis data
Database-backed records only
| valuation date | price | market cap | enterprise value | pe | forward pe | peg | price sales | price book | price fcf |
|---|---|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | 2.71 | $223,400,723.24 | 182399723.24 | 12.2272727272727273 | — | — | 6.6192806885925926 | 3.3229814996504485 | 8.50596722662199208038 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.